PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25869206-5 2015 We characterized two enzymes, PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and report increased efficacy of established anti-androgens in combination with a clinically approved IMPDH inhibitor, mycophenolic acid (MPA). Mycophenolic Acid 222-239 inosine monophosphate dehydrogenase 2 Homo sapiens 40-46 26467706-0 2016 Differential Sensitivities of Fast- and Slow-Cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid. Mycophenolic Acid 121-138 inosine monophosphate dehydrogenase 2 Homo sapiens 69-106 25869206-5 2015 We characterized two enzymes, PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and report increased efficacy of established anti-androgens in combination with a clinically approved IMPDH inhibitor, mycophenolic acid (MPA). Mycophenolic Acid 241-244 inosine monophosphate dehydrogenase 2 Homo sapiens 40-46 19299544-1 2009 BACKGROUND: The immunosuppressive effect of mycophenolic acid (MPA) is essentially attributed to IMPDH II inhibition, which leads to a reduction of lymphocyte proliferation. Mycophenolic Acid 44-61 inosine monophosphate dehydrogenase 2 Homo sapiens 97-105 20718729-0 2010 Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics. Mycophenolic Acid 24-41 inosine monophosphate dehydrogenase 2 Homo sapiens 98-104 20718729-1 2010 BACKGROUND AND PURPOSE: Inosine monophosphate dehydrogenases, encoded by IMPDH1 and IMPDH2, are targets for the important immunosuppressive drug, mycophenolic acid (MPA). Mycophenolic Acid 146-163 inosine monophosphate dehydrogenase 2 Homo sapiens 84-90 20718729-1 2010 BACKGROUND AND PURPOSE: Inosine monophosphate dehydrogenases, encoded by IMPDH1 and IMPDH2, are targets for the important immunosuppressive drug, mycophenolic acid (MPA). Mycophenolic Acid 165-168 inosine monophosphate dehydrogenase 2 Homo sapiens 84-90 19299544-1 2009 BACKGROUND: The immunosuppressive effect of mycophenolic acid (MPA) is essentially attributed to IMPDH II inhibition, which leads to a reduction of lymphocyte proliferation. Mycophenolic Acid 63-66 inosine monophosphate dehydrogenase 2 Homo sapiens 97-105 17496727-2 2007 Variants in the IMPDH2 gene may account for the large inter-individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving mycophenolic acid. Mycophenolic Acid 191-208 inosine monophosphate dehydrogenase 2 Homo sapiens 16-22 18976158-1 2008 Inosine monophosphate dehydrogenase type II (IMPDH2) is the target for immunosuppression by mycophenolic acid and has been linked to resistance of tumor cells to chemotherapy. Mycophenolic Acid 92-109 inosine monophosphate dehydrogenase 2 Homo sapiens 0-43 18976158-1 2008 Inosine monophosphate dehydrogenase type II (IMPDH2) is the target for immunosuppression by mycophenolic acid and has been linked to resistance of tumor cells to chemotherapy. Mycophenolic Acid 92-109 inosine monophosphate dehydrogenase 2 Homo sapiens 45-51 17805303-4 2007 One gene is a variant of the inosine monophosphate dehydrogenase 2, inosine monophosphate dehydrogenase (IMPDH(IY)), conferring resistance to the immunosuppressive drug mycophenolate mofetil (MMF). Mycophenolic Acid 169-190 inosine monophosphate dehydrogenase 2 Homo sapiens 29-66 17805303-4 2007 One gene is a variant of the inosine monophosphate dehydrogenase 2, inosine monophosphate dehydrogenase (IMPDH(IY)), conferring resistance to the immunosuppressive drug mycophenolate mofetil (MMF). Mycophenolic Acid 192-195 inosine monophosphate dehydrogenase 2 Homo sapiens 29-66 15621150-2 2004 It inhibits the inducible isoform of the enzyme inosine-monophosphate dehydrogenase (IMPDH II) via its active metabolite mycophenolic acid (MPA). Mycophenolic Acid 121-138 inosine monophosphate dehydrogenase 2 Homo sapiens 85-93 15614187-10 2005 Changes in IMPDH2 mRNA levels were confirmed and functional analyses were performed by inhibiting IMPDH with either benzamide riboside, mycophenolic acid, or tiazofurin. Mycophenolic Acid 136-153 inosine monophosphate dehydrogenase 2 Homo sapiens 11-17 15621150-2 2004 It inhibits the inducible isoform of the enzyme inosine-monophosphate dehydrogenase (IMPDH II) via its active metabolite mycophenolic acid (MPA). Mycophenolic Acid 140-143 inosine monophosphate dehydrogenase 2 Homo sapiens 85-93 30442353-0 2018 Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil. Mycophenolic Acid 125-146 inosine monophosphate dehydrogenase 2 Homo sapiens 17-23 34075374-7 2021 We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction. Mycophenolic Acid 131-148 inosine monophosphate dehydrogenase 2 Homo sapiens 23-29 34075374-7 2021 We confirmed the Nsp14-IMPDH2 protein interaction and found that IMPDH2 knockdown or chemical inhibition using ribavirin (RIB) and mycophenolic acid (MPA) abolishes Nsp14-mediated NF-kappaB activation and cytokine induction. Mycophenolic Acid 150-153 inosine monophosphate dehydrogenase 2 Homo sapiens 23-29 35524809-8 2022 CONCLUSIONS: IMPDH1, IMPDH2, and UGT1A9 polymorphisms were associated with rejection in kidney transplant recipients, and the genetic backgrounds of patients should be considered when using MPA. Mycophenolic Acid 190-193 inosine monophosphate dehydrogenase 2 Homo sapiens 21-27 33855339-9 2021 Targeting the ARLI3B-IMPDH2 circuit can be achieved using the Food and Drug Administration-approved drug, mycophenolate mofetil, which can block IMPDH2 activity and enhance the therapeutic efficacy of temozolomide. Mycophenolic Acid 106-127 inosine monophosphate dehydrogenase 2 Homo sapiens 21-27 33855339-9 2021 Targeting the ARLI3B-IMPDH2 circuit can be achieved using the Food and Drug Administration-approved drug, mycophenolate mofetil, which can block IMPDH2 activity and enhance the therapeutic efficacy of temozolomide. Mycophenolic Acid 106-127 inosine monophosphate dehydrogenase 2 Homo sapiens 145-151 32949604-2 2020 Recent advances in the role of the type II isoform of inosine-5"-monophosphate dehydrogenase (IMPDH2) in the tumorigenesis of various types of cancer have called for a second look of MPA, the first IMPDH2 inhibitor discovered a hundred years ago, to be repurposed as an anticancer agent. Mycophenolic Acid 183-186 inosine monophosphate dehydrogenase 2 Homo sapiens 94-100 30223117-8 2018 Most of the compounds exhibited higher cellular potency against cancer cell lines and notably lower toxicity towards NIH-3T3 cells compared to mycophenolic acid (MPA), a prototypical hIMPDH2 inhibitor. Mycophenolic Acid 143-160 inosine monophosphate dehydrogenase 2 Homo sapiens 183-190 30056902-4 2018 STUDY DESIGN: In an observational longitudinal study of kidney transplant recipients treated with mycophenolate mofetil, genetic factors were IMPDH1 (rs2278294, rs2278293) and IMPDH2 (rs11706052) allelic variants, the main outcome was the time-dependent change in BMI, and secondary outcomes were occurrence of BMI below 18.5 or 20 kg/m2. Mycophenolic Acid 98-119 inosine monophosphate dehydrogenase 2 Homo sapiens 176-182